Syntara shows encouraging first signals it can impact the path to Parkinson's
Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence that the company’s novel anti-inflammatory therapy may be targeting a key biological process linked to the development of Parkinson’...
Market Cap $13.84M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
Filters
[Clear]
- Price Sensitive: Yes
| MHC | Manhattan Update on TTR Merger and Acquisition | PRICE SENSITIVE | 11/04/18 | |
| MHC | Manhattan to Acquire Trans-Tasman Resources Limited | PRICE SENSITIVE | 23/01/18 | |
| MHC Manhattan Update on TTR Merger and Acquisition | |||
| 11/04/18 | PRICE SENSITIVE | ||
| MHC Manhattan to Acquire Trans-Tasman Resources Limited | |||
| 23/01/18 | PRICE SENSITIVE | ||
